P2RY6

Across TCGA pan-cancer cohorts, P2RY6 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated P2RY6 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher P2RY6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated P2RY6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, SKCM, and BLCA are the cancer types where P2RY6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.152	0.525	.006	12	view →
SKCM	OS	Median	All	0.197	0.873	<.001	12	view →
BLCA	OS	Median	III,IV	0.188	0.654	.015	9	view →
SARC	OS	Median	All	0.143	0.745	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.258	0.787	.018	6	view →
UCEC	DFS	Median	All	0.957	0.623	.025	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

P2RY6–ESCA (DFS)

Open the ESCA breakdown →